First‐in‐human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy
Allergy2022Vol. 77(10), pp. 3096–3107
Citations Over TimeTop 10% of 2022 papers
Antonio Nieto, Ángel Mazón, María Nieto, Ethel Ibáñez-Echevarría, Dah Tay Jang, Susana Calaforra, Pilar Alba, Carmen Pérez‐Francés, Ruth Llusar, Javier Montoro, Antonio de Mateo, Remedios Alamar, David El‐Qutob, Javier Fernández, Luis Moral, Teresa Toral, Mónica Antón, Carmen Andréu, A. Ferrer, Isabel‐María Flores, Neus Cerdá, Sandra del Pozo, Raquel Caballero, José Luis Subiza, Miguel Casanovas
Abstract
PM-HDM immunotherapy was safe and successful in achieving primary and secondary clinical outcomes in SC and SL at either 3000 or 5000 mTU/ml.
Related Papers
- → Overview of Component Resolved Diagnostics(2012)106 cited
- → Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen(2016)40 cited
- → Identification of a novel cofilin-related molecule (Der f 31) as an allergen from Dermatophagoides farinae(2017)10 cited
- → Der f 16: a novel gelsolin‐related molecule identified as an allergen from the house dust mite, Dermatophagoides farinae1(2002)23 cited
- → The Major Allergen of the House Dust Mite, <i>Dermatophagoides pteronyssinus</i>, Is Synthesized and Secreted into Its Alimentary Canal(1988)19 cited